gemcitabine hydrochloride + paclitaxel
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Jul 1, 2000 → Oct 1, 2005
NCT ID
NCT00006459About gemcitabine hydrochloride + paclitaxel
gemcitabine hydrochloride + paclitaxel is a phase 3 stage product being developed by Eli Lilly for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00006459. Target conditions include Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00006459 | Phase 3 | Completed |
Competing Products
20 competing products in Breast Cancer